Related Experiment Video
Updated: Feb 25, 2026
07:01
Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
Published on: August 19, 2025
1.1K
Serum Hepcidin Levels in Multiple Myeloma
Clinical Laboratory
|August 10, 2017
Summary
Multiple myeloma patients have significantly higher hepcidin levels, indicating its role in iron homeostasis disorders. This finding is crucial for managing anemia in multiple myeloma.
Area of Science:
- Hematology
- Oncology
- Biochemistry
Background:
- Multiple myeloma (MM) is a plasma cell malignancy impacting bone marrow, often leading to anemia and kidney failure.
- Interleukin-6 (IL-6) is an inflammatory cytokine linked to poor prognosis in MM and influences acute-phase protein synthesis.
- Hepcidin, regulated by IL-6, plays a key role in iron metabolism.
Purpose of the Study:
- To investigate the role of hepcidin in iron homeostasis in multiple myeloma patients.
- To compare hepcidin, IL-6, and C-reactive protein (CRP) levels in newly diagnosed MM patients versus healthy controls.
- To explore correlations between hepcidin, IL-6, CRP, and iron parameters in MM.
Main Methods:
- Evaluated 21 newly diagnosed multiple myeloma patients and 21 age-matched controls before treatment.
- Measured complete blood count (CBC), iron studies (serum iron, TIBC, ferritin), soluble transferrin receptors, IL-6, and hepcidin.
- Analyzed correlations between measured parameters.
Main Results:
- Serum hepcidin levels were significantly elevated in MM patients (99.4 ± 10.5 µg/L) compared to controls (19.9 ± 2.8 µg/L).
- IL-6 and CRP levels were also elevated in MM patients.
- Strong negative correlations were observed between hepcidin and IL-6 (r = -0.894) and CRP (r = -0.916).
- Hepcidin showed negative correlation with soluble transferrin receptors (r = -0.831) and positive correlation with transferrin (r = 0.580).
Conclusions:
- Hepcidin plays a significant role in iron homeostasis disorders in multiple myeloma.
- Elevated hepcidin concentrations are characteristic of multiple myeloma patients.
- Managing anemia associated with multiple myeloma remains a clinical challenge.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
243
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
243
01:24Serum Studies: Renal Function Tests
490
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
490
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
294
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
294